Browsing Brage INN by Author "Eggen, Anne Elise"
Now showing items 1-5 of 5
-
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption – an individual-level prescription database study
Hartz, Ingeborg; Sakshaug, Solveig; Furu, Kari; Engeland, Anders; Eggen, Anne Elise; Njølstad, Inger; Skurtveit, Svetlana (Journal article; Peer reviewed, 2007)BACKGROUND: A previous study has shown that variations in threshold and intensity (lipid goal attainment) of statins for primary prevention contribute to regional differences in overall consumption of statins in Norway. ... -
Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromsø Study 2001
Melbye, Hasse; Halvorsen, Dag; Hartz, Ingeborg; Medbøe, Astri; Brox, Jan; Eggen, Anne Elise; Njølstad, Inger (Journal article; Peer reviewed, 2007)Background: Bronchial airflow limitation is a known predictor of raised C-reactive protein (CRP) level. The aim of this study was to explore this association in an elderly population, as well as the influence of other known ... -
Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001
Hartz, Ingeborg; Njølstad, Inger; Eggen, Anne Elise (Journal article; Peer reviewed, 2005)Aims To study the implications of European guidelines on the use of antihypertensives and/or lipidlowering drugs (LLDs) for primary prevention in a Norwegian population. Methods and results The Tromsø study is a ... -
Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001
Hartz, Ingeborg; Eggen, Anne Elise; Grimsgaard, Sameline; Skjold, Frode; Njølstad, Inger (Journal article; Peer reviewed, 2004)Abstract Objective: The beneficial effect of lipid-lowering drugs (LLDs) is well documented. Despite increasing sales of LLDs, little is known about what characterizes LLD users. Our objective was to describe LLD users ... -
Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000 /2001
Hartz, Ingeborg; Skurtveit, Svetlana; Furu, Kari; Njølstad, Inger; Eggen, Anne Elise (Journal article; Peer reviewed, 2006)Objective. To study and compare plausible factors that might explain varying sales of lipid-lowering drugs (LLDs) in the two neighbouring counties of Hedmark and Oppland in Norway, with a similar age distribution, ...